2Bresalier RS, Sandier RS, Quan H, et al. Cardiovascular events Associated with rofecoxib in a colorectal adenoma chemop revention trial[J]. N Engl J Med, 2005, 352:1092-1102.
3Solomon SD, McMurray JV, Pfefer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma P revention[ J]. N Engl J Med, 2005, 352:1071-1080.
4Mukherjee D, Nissen SE, Topoi EJ. Risk of cardiovascular events assoc iated with selective COX-2 inhibitors[ J]. JAMA, 2002, 286 (8) :954.
5Stichtenoth DO, Frolich JC. The second generation of COX-2 inhibitors: What advantages do the Newest offer[ J ] ? Drugs, 2003, 63(1) :33-45.
6Miceli-Richard C, Dougados M. NSAIDs in ankylosing spondylitis [J]. Clin Exp Rheumatol, 2002, 20(6 Suppl 28) :S65-66.
